RSS

high potency active pharmaceutical ingredients (HPAPIs)

Not all highly potent compounds require extreme containment. In this article, Jeff Pavlovich, senior process safety engineer at Cambrex Charles City, examines the intricacies of risk assessment and the importance of a realistic approach. more

Latest Issue

Michael Avraam, global product manager at ChargePoint Technology discusses the evolution of containment strategies, specifically within the role of containment verification and monitoring technology. more

Opinion

Minakem, the contract development and manufacturing organisation (CDMO) division of Minafin, has revealed it is in the final qualification run to open a new closed-controlled environment high containment production facility in August. more

News

More and more newer drugs contain high potency active pharmaceutical ingredients (APIs), which require careful handling and specialised equipment. Here, Precision Polymer Engineering (PPE) highlights why split butterfly valves offer a cost-effective more

Opinion

In this article, Michael Avraam, global product manager at ChargePoint Technology discusses the potential issues with containment performance testing some techniques and developments that may help to ensure efficiency more

Opinion

Supplier to the pharma, biotech and specialty ingredients markets, Lonza, has expanded its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in the US. more

Technology

Demand for high potent active pharmaceutical ingredients is driving the need for high potency handling capabilities. Here, Mike Avraam, global product manager for ChargePoint PharmaSafe, ChargePoint Technology, discusses this growing sector in detail more

Opinion

Sylvain Querol (MEng), tendering manager, Europe, at Powder Systems Limited on how to achieve high containment for HPAPI small-scale production. more

News

As 2015 is beginning to wrap up European Pharmaceutical Manufacturer has looked at our most popular stories more

News

Capsugel is set to more than double the size of its facility in Edinburgh, Scotland, enabling the company to meet rising customer demand for its liquid- and semi-solid-fill hard capsule development and manufacturing services. more

News

Reddy made

Dr. Reddy's Custom Pharmaceutical Services (CPS) explains the integration of highly potent drug substance and drug product manufacturing. more

3 Oct 2014 11:04 Guest Blogs

Novasep’s €4 million (£3.3/$5.5 million) investment to expand its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities at its Le Mans facility in France has reached fruition. The plant extension has been fully... more

Technology

Dec Group multi-purpose isolators are designed for use in pharmaceutical manufacturing areas for the contamination-free handling of HPAPIs. The containment systems are developed with Dec’s ergonomic package to offer ease of use and an ultra-safe ... more

Technology

Novasep has announced that the FDA successfully audited two of its European custom manufacturing sites in Le Mans, France and Leverkusen, Germany. FDA investigators audited the two facilities in June and July 2013. more

Technology

To meet rising demand for high potency active pharmaceutical ingredients (HPAPIs) spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Switzerland-based CARBOGEN AMCIS has completed a capital... more

Technology

Sigma-Aldrich Corporation’s custom manufacturing services business unit, SAFC Commercial (www.sigma-aldrich.com/safc), is expanding two of its manufacturing facilities in the US to support drug manufacturers in efficiently bringing new targeted... more

Technology